ANKE BIO(300009)2022-10-25 16:00Financial Performance - The company's revenue for Q3 2022 reached ¥625,956,544.57, an increase of 8.27% compared to the same period last year[2] - Net profit attributable to shareholders was ¥249,847,600.64, representing a growth of 34.78% year-on-year[2] - The net profit excluding non-recurring gains and losses was ¥242,327,512.42, up by 34.33% compared to the previous year[2] - The company achieved a revenue of RMB 1,130.59 million for the first nine months, representing an 18.80% increase year-over-year[11] - Operating profit for the same period was RMB 716.23 million, up 52.84% compared to the previous year[11] - Net profit reached RMB 620.26 million, reflecting a 55.48% growth year-over-year[11] - Total operating revenue for the third quarter reached CNY 1,706,679,675.63, an increase from CNY 1,547,398,225.09 in the same period last year, representing a growth of approximately 10.3%[20] - The net profit for the third quarter reached CNY 605 million, compared to CNY 431 million in the previous year, marking an increase of approximately 40.2%[21] - The basic and diluted earnings per share were both CNY 0.36, up from CNY 0.26 in the same quarter last year, reflecting a growth of 38.5%[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,857,085,448.77, reflecting a 5.12% increase from the end of the previous year[2] - As of September 30, 2022, the total current assets amounted to CNY 1,842,564,182.61, a decrease of 4.1% from CNY 1,921,622,830.59 at the beginning of the year[17] - Non-current assets totaled CNY 2,014,521,266.16, up from CNY 1,747,463,145.48, marking an increase of about 15.3%[19] - The company's total liabilities decreased to CNY 637,284,242.05 from CNY 765,521,209.36, a reduction of about 16.7%[19] - The total equity attributable to shareholders increased to CNY 3,044,930,352.46 from CNY 2,786,596,726.38, representing a growth of approximately 9.3%[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥441,638,832.27, showing a 9.97% increase compared to the same period last year[2] - The net cash flow from operating activities was CNY 441.64 million, an increase from CNY 401.59 million year-over-year, representing a growth of about 9.9%[24] - The company reported a net cash outflow from investing activities of approximately CNY 191.14 million, compared to a net outflow of CNY 167.24 million in the previous year[24] - Cash and cash equivalents decreased to CNY 247,421,616.05 from CNY 322,563,322.59, reflecting a decline of 23.3%[17] - The company’s cash and cash equivalents at the end of the quarter were CNY 247.04 million, up from CNY 122.99 million at the end of the same quarter last year[24] Investments and Development - Long-term equity investments increased by 48.15% to ¥185,099,352.61, attributed to investments in joint ventures[5] - The company plans to expand its production capacity with significant investments in new facilities for antibody and protein drug production[5] - The company is focusing on enhancing its product offerings and market expansion as part of its growth strategy[16] - Future outlook includes continued investment in R&D and potential market expansion strategies, although specific targets were not detailed in the report[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 78,499[8] - Major shareholder Song Lihua holds 26.52% of the shares, with a total of 434,578,710 shares[8] - The company has a total of 466,567,577 restricted shares, with no new restricted shares added during the reporting period[10] - The company plans to use repurchased shares for equity incentives or employee stock ownership plans[11] - The company will implement the third phase of the restricted stock incentive plan, granting 40 million restricted shares, accounting for approximately 2.4413% of the total share capital at the time of the plan announcement[13] Research and Development - Research and development expenses were CNY 107,940,546.47, compared to CNY 100,716,322.52 in the previous year, reflecting an increase of approximately 7.3%[20] - The company is in the process of implementing a third phase of the restricted stock incentive plan, which was discussed in the board meetings held in September 2022[16] - The company has received independent financial advisory reports regarding the third phase of the restricted stock incentive plan, indicating ongoing strategic initiatives[16] Corporate Governance - The company aims to enhance its corporate governance structure and long-term incentive mechanisms to motivate its core team[13] - The company has disclosed multiple announcements regarding the repurchase of shares, with the first repurchase occurring on March 9, 2022[14] - The company has consistently reported progress on share repurchases throughout 2022, with updates provided in March, April, May, June, July, August, and the final results announced on August 8, 2022[14]